Overview

A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Status:
NOT_YET_RECRUITING

Trial end date:
2028-12-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

Phase:

PHASE2

Details

Lead Sponsor:

Vertex Pharmaceuticals Incorporated

Treatments:

Tacrolimus